Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Summit Therapeutics Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $35.84, while Summit Therapeutics Inc trades at $15.09 (market cap $12.01B). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BOTZ | SMMT | |
|---|---|---|
52-Week High | $41.63 | $29.32 |
52-Week Low | $31.99 | $13.05 |
Market Cap | — | $12.01B |
Sector | — | Health |
Enterprise Value | — | $11.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
